Trial · NCT02118584
Adverse events502
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 502
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part 1 (OLE): Etrolizumab | 128 | 1,773 | 149 |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 (PML SM) | 0 | 796 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Part 1 (OLE): Etrolizumab | 98 | 1,773 | 117 |
| other | Abdominal pain | Gastrointestinal disorders | Part 2 (PML SM) | 0 | 796 | 0 |
| other | Colitis ulcerative | Gastrointestinal disorders | Part 1 (OLE): Etrolizumab | 587 | 1,773 | 882 |
| other | Colitis ulcerative | Gastrointestinal disorders | Part 2 (PML SM) | 2 | 796 | 2 |
| other | Diarrhoea | Gastrointestinal disorders | Part 1 (OLE): Etrolizumab | 95 | 1,773 | 114 |
| other | Diarrhoea | Gastrointestinal disorders | Part 2 (PML SM) | 0 | 796 | 0 |
| other | COVID-19 | Infections and infestations | Part 1 (OLE): Etrolizumab | 165 | 1,773 | 178 |
| other | COVID-19 | Infections and infestations | Part 2 (PML SM) | 0 | 796 | 0 |
| other | Influenza | Infections and infestations | Part 1 (OLE): Etrolizumab | 100 | 1,773 | 121 |
| other | Influenza | Infections and infestations | Part 2 (PML SM) | 0 | 796 | 0 |
| other | Nasopharyngitis | Infections and infestations | Part 1 (OLE): Etrolizumab | 226 | 1,773 | 344 |
| other | Nasopharyngitis | Infections and infestations | Part 2 (PML SM) | 0 | 796 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Part 1 (OLE): Etrolizumab | 110 | 1,773 | 157 |
| other | Upper respiratory tract infection | Infections and infestations | Part 2 (PML SM) | 0 | 796 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Part 1 (OLE): Etrolizumab | 128 | 1,773 | 172 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Part 2 (PML SM) | 0 | 796 | 0 |
| other | Headache | Nervous system disorders | Part 1 (OLE): Etrolizumab | 134 | 1,773 | 187 |
| other | Headache | Nervous system disorders | Part 2 (PML SM) | 0 | 796 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02118584/events